multiple sclerosis

Businessman climbing steps to pluck a star from the sky
Biotech

Roche links BTK drug to low relapse rate across 96-week MS trial

The phase 2 data provide evidence of durability of fenebrutinib over 96 weeks ahead of the release of pivotal trial results.
Nick Paul Taylor May 30, 2025 5:19am
arrow miss target fail attempt try

Immunic MS asset misses primary goal of midstage trial

Apr 30, 2025 3:05pm
MA strategy deal block push come together form

Acelyrin to be absorbed into Alumis in all-stock merger

Feb 7, 2025 5:35am
Image comparing healthy and degraded myelin sheath

Investigational MS drug restores mobility in mice

Jan 2, 2025 2:15pm
lightbulb explosion art

Sanofi will deploy new AI tool in late-stage MS trials

Nov 13, 2024 7:40am
failure crash no fail rocket cancelled end

Sanofi flunks MS study, dealing another blow to Denali pact

Oct 11, 2024 5:56am